• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Evaluation of Automatic Class III Designation (De Novo) Summaries

The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the "De Novo" classification option as an alternate pathway to classify certain new devices that had automatically been placed in Class III due to lack of a predicate.

The De Novo process applies to low and moderate risk devices that have been classified as class III because they were found not substantially equivalent (NSE) to existing devices. Applicants who receive this determination may request a risk-based evaluation for reclassification into class I or II within 30 days of receipt of an NSE determination. Devices that are classified through the De Novo process may be marketed and used as a predicate for future Premarket Notification [510(k)] submissions.

FDA has begun releasing De Novo Summary documents for devices granted market authority through the De Novo process. The De Novo Summary is intended to present an objective and balanced summary of the scientific evidence that served as the basis of the decision to grant a de novo petition. The Summary outlines how FDA determined that the device for which a petition is granted is low to moderate risk and that general and/or special controls provide reasonable assurance of safety and effectiveness. The De Novo Summary also serves as a resource on the types of information necessary to support substantial equivalence for device manufacturers that may wish to use the de novo device as a predicate for future 510(k) submissions.

Links to all available De Novo Summary documents can be found in the table below.

Device Name510(k) NumberApproval LetterDecision Summary
Infrascanner Model 1000K080377Approval Letter 
Zeltiq™ Dermal Cooling DeviceK080521Approval Letter 
Erchonia ML ScannerK082609Approval Letter 
NuMED NuCLEUS and NuCLEUS-X BAV CathetersK082776Approval LetterDecision Summary
Hem-Avert Perianal StabilizerK083692Approval Letter 
RIDASCREEN Norovirus 3rd Generation EIAK093295Approval Letter 
Prostate Mechanical ImagerK093579Approval LetterDecision Summary
LipiFlow Thermal Pulsation SystemK093937Approval Letter 
Steris Verify Spore Test Strip for S40K100049Approval LetterDecision Summary
InBios DENV Detect IgM Capture ELISAK100534Approval LetterDecision Summary
Widex C4-PA Wireless Air-Conduction Hearing AidK101699Approval LetterDecision Summary
Aptus Endovascular Suturing SystemK102333Approval LetterDecision Summary
ImmunoCAP TryptaseK103039Approval LetterDecision Summary
Percutaneous Surgical Set with 5 mm or 10 mm AttachmentsK110431Approval LetterDecision Summary
STRATIFY JCV Antibody ELISAK112394Approval LetterDecision Summary
Proteus Personal Monitor Including Ingestion Event MarkerK113070Approval LetterDecision Summary
PORTRAIT TOXIGENIC C. DIFFICILE ASSAYK113358Approval LetterDecision Summary
Verigene® Gram Positive Blood Culture Nucleic Acid Test (BC-GP)K113450Approval LetterDecision Summary
xTAG® Gastrointestinal Pathogen Panel (GPP)K121454Approval LetterDecision Summary
FerriScan R2-MRI Analysis SystemK124065Approval LetterDecision Summary

 

-
-